Regenerex Pharma (RGPX) 10-Q 2 Feb 22 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Dec. 31, 2021	Feb. 02, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--03-31
Entity File Number	000-53230
Entity Registrant Name	REGENEREX PHARMA, INC.
Entity Central Index Key	0001357878
Entity Tax Identification Number	98-0479983
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5348 Vegas Drive #177
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89108
City Area Code	(702)
Local Phone Number	273-3772
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		277,112,660
Entity Information, Former Legal or Registered Name	Peptide Technologies, Inc.

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2021	Mar. 31, 2021
Current Assets
Cash and equivalents	$ 2,789	$ 6,902
Prepaid expenses		1,213
Total Current Assets	2,789	8,115
Website, net of accumulated amortization of $21,974 and $19,645, respectively	8,626	2,355
Total Assets	11,415	10,470
Current Liabilities
Accounts payable	47,813	48,038
Related party advances	131,447	130,992
Accrued compensation	221,192	221,192
Other accrued liabilities	79,524	71,003
Current portion of notes payable to shareholder	118,853	150,094
Total Current Liabilities	598,829	621,319
Notes payable to shareholder, net of current portion	349,754	224,177
Total Liabilities	948,583	845,496
Common stock: $0.001 par value: 675,000,000 shares authorized: 277,112,660 and 127,112,660 issued and outstanding at December 31, 2021 and March 31, 2021, respectively	277,113	127,113
Additional paid-in capital	671,963	776,963
Accumulated deficit	(1,886,244)	(1,739,102)
Total Stockholders’ Deficit	(937,168)	(835,026)
Total Liabilities and Stockholders’ Deficit	$ 11,415	$ 10,470

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2021	Mar. 31, 2021
Statement of Financial Position [Abstract]
Accumulated Amortization, Website	$ 21,974	$ 19,645
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	675,000,000	675,000,000
Common Stock, Shares, Issued	277,112,660	127,112,660
Common Stock, Shares, Outstanding	277,112,660	127,112,660

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Sales		$ 181		$ 378
Cost of Sales		364		406
Gross Loss		(183)		(28)
Operating Expenses
General and administrative	62,385	12,103	100,192	33,229
Sales and marketing	612	1,966	3,303	3,056
Total Operating Expenses	62,997	14,069	103,495	36,285
Operating Loss	(62,997)	(14,252)	(103,495)	(36,313)
Other Income (Expense)
Interest expense	(14,548)	(11,203)	(44,130)	(31,335)
Foreign currency gain (loss)	(1,889)	(8,228)	483	(1,624)
Total Other Income (Expense)	(16,437)	(19,431)	(43,647)	(32,959)
Net Loss	$ (79,434)	$ (33,683)	$ (147,142)	$ (69,272)
Basic and Diluted Loss per Common Share	$ 0	$ 0	$ 0	$ 0
Weighted Average Number of Common Shares Outstanding	203,743,095	127,112,660	152,749,024	127,112,660

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash Flows from Operating Activities:
Net loss	$ (147,142)	$ (69,272)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation	2,329	4,167
Foreign currency adjustments	(483)	1,624
Stock-based compensation	45,000
Changes in operating assets and liabilities:
Inventories		406
Prepaid expenses	1,213	(1,645)
Accounts payable and accrued liabilities	36,033	27,168
Net cash used in operating activities	(63,050)	(37,552)
Cash Flows from Investing Activities:
Website	(8,600)
Net cash used in investing activities	(8,600)
Cash Flows from Financing Activities:
Related party advances	455
Proceeds from notes payable to shareholder	67,082	33,813
Net cash provided by financing activities	67,537	33,813
Decrease in cash and equivalents	(4,113)	(3,739)
Cash and cash equivalents, beginning of period	6,902	5,460
Cash and cash equivalents, end of period	2,789	1,721
Income Taxes
Interest
Non-Cash Investing and Financing Activities:
Accrued interest converted into note payable to shareholder	$ 27,254

STATEMENTS OF STOCKHOLDERS' DIF

STATEMENTS OF STOCKHOLDERS' DIFICIT - USD ($)	3 Months Ended		6 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Balance at September 30, 2021	$ (902,734)	$ (516,863)	$ (835,026)	$ (481,274)	$ (835,026)	$ (481,274)
Common Stock, Shares, Outstanding, Beginning Balance			127,112,660		127,112,660
Net Loss	(79,434)	(33,683)	$ (67,708)	(35,589)	$ (147,142)	(69,272)
Balance at December 31, 2021	$ (937,168)	(550,546)	(902,734)	(516,863)	$ (937,168)	(550,546)
Common Stock, Shares, Outstanding, Ending Balance	277,112,660				277,112,660
Common stock issued for purchase of intellectual property
Stock-based compensation	45,000
Common Stock [Member]
Balance at September 30, 2021	$ 127,113	$ 127,113	$ 127,113	$ 127,113	$ 127,113	$ 127,113
Common Stock, Shares, Outstanding, Beginning Balance	127,112,660	127,112,660	127,112,660	127,112,660	127,112,660	127,112,660
Net Loss
Balance at December 31, 2021	$ 277,113	$ 127,113	$ 127,113	$ 127,113	$ 277,113	$ 127,113
Common Stock, Shares, Outstanding, Ending Balance	277,112,660	127,112,660	127,112,660	127,112,660	277,112,660	127,112,660
Common stock issued for purchase of intellectual property	150,000
Common stock issued for purchase of intellectual property	150,000,000
Stock-based compensation
Additional Paid-in Capital [Member]
Balance at September 30, 2021	$ 776,963	$ 776,963	$ 776,963	$ 776,963	$ 776,963	$ 776,963
Net Loss
Balance at December 31, 2021	$ 671,963	776,963	776,963	776,963	671,963	776,963
Common stock issued for purchase of intellectual property	(150,000)
Stock-based compensation	45,000
Retained Earnings [Member]
Balance at September 30, 2021	$ (1,806,810)	(1,420,939)	(1,739,102)	(1,385,350)	(1,739,102)	(1,385,350)
Net Loss	(79,434)	(33,683)	(67,708)	(35,589)
Balance at December 31, 2021	$ (1,886,244)	$ (1,454,622)	$ (1,806,810)	$ (1,420,939)	$ (1,886,244)	$ (1,454,622)
Common stock issued for purchase of intellectual property
Stock-based compensation

NATURE OF OPERATIONS

NATURE OF OPERATIONS	9 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NOTE 1 – NATURE OF OPERATIONS Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on . The Company’s business was to develop and market proprietary skincare products that was to be sold online. The majority of manufacturing, distribution, marketing, and sales operations was outsourced. The Company’s attempt over the past four years to build a business that marketed skincare products online has not come to fruition, so management decided to change the business focus and look for other opportunities. On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15 th Management has decided to focus on this new business development. Risks and Uncertainties Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position and cash flows. The Company has a lack of revenue history and has had a limited history of operations. No revenue has historically been derived from the assets purchased. Regenerex can give no assurance of success or profitability to the Company’s investors.

BASIS OF PRESENTATION OF INTERI

BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS	9 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS	NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ending March 31, 2022. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended March 31, 2021 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2021 included within the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations, and as of December 31, 2021, it had excess liabilities over assets of $937,168 These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company requires significant cash to launch its business and reduce its payable. Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government. The Company defers revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1. Earnings per Share Earnings per share is reported in accordance with FASB Accounting Standards Codification (“ASC”) Topic 260 “ Earnings per Share December 31 , 2021 and 2020, the Company does not have any common share equivalents outstanding. Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2021 and 2020 was $ and $ and $ and $ , respectively. Recent Accounting Pronouncements The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 5 – RELATED PARTY TRANSACTIONS The Company purchased assets from the Company’s current Chief Executive Officer (“CEO”) and Secretary/Treasurer (see note 6). Related Party Advances The Company’s former Chief Financial Officer (“CFO”) has historically advanced the Company monies for operating expenses; Advances during the nine-month period December 31, 2021 and 2020 were $455 and $0, respectively. The related party advances totaled $ and $ as of December 31, 2021 and March 31, 2021, respectively. The advances are due on demand. The related party advances accrue interest at ten (10) percent per annum. Repayment is due no later than June 30, 2023. Interest expense was $ and $ during the nine-month periods ended December 31, 2021 and 2020, respectively. Note Payables to Shareholders As at December 31, 2021 and March 31, 2021, the Company had various promissory notes with total outstanding principal balances of $468,607 and $374,271, respectively, due to a shareholder of the Company. These notes are unsecured, bear interest at 10% per annum, and have maturity dates ranging from January 20, 2022 to December 30, 2023. On April 15, 2021, one note to a shareholder that was originally due on April 15, 2021 with a principal amount of approximately $72,000 ($90,000 Canadian Funds) was reissued in the principal amount of approximately $86,000 ($108,000 Canadian Funds) which included the original principal amount plus interest accrued as at April 15, 2021 in the amount of approximately $14,000 ($18,000 Canadian Funds). Repayment of the note is due no later than April 15, 2023. On October 11, 2021 one note to a shareholder that was originally due on October 11, 2021 with a principal amount of $10,000 was reissued in the principal amount of $12,000 which included the original principal plus interest accrued as at October 11, 2021 in the amount of $2,000. Repayment of the note is due no later than October 11, 2023. On October 21, 2021, one note to a shareholder that was originally due on October 21, 2021 with a principal amount of $30,000 was reissued in the principal amount of $36,000 which included the original principal plus interest accrued as at October 21, 2021 in the amount of $6,000. Repayment of the note is due no later than October 21, 2023. On October 25, 2021, one note to a shareholder that was originally due on October 25, 2021 with a principal amount of $24,500 was reissued in the principal amount of $29,400 which included the original principal plus interest accrued as at October 25, 2021 in the amount of $4,900. Repayment of the note is due no later than October 25, 2023. On December 9, 2021, one note to a shareholder that was originally due on December 9, 2021 with a principal amount of approximately $4,000 ($5,000 Canadian Funds) was reissued in the principal amount of approximately $5,000 ($6,000 Canadian Funds) which included the original principal plus interest accrued as at December 9, 2021 in the amount of approximately $758 ($1,000 Canadian Funds). Repayment of the note is due no later than December 9, 2023. During the nine-month period ended December 31, 2021, a shareholder was issued additional eight (8) promissory notes totaling $67,082 ($86,500 Canadian Funds). These notes are unsecured and bear interest at ten (10) percent per annum with principal and interest due twenty-four (24) months after the date of issue. Accrued interest was $42,676 and $33,132 as of December 31, 2021 and March 31, 2021, respectively, which is included in other accrued liabilities.

INTANGIBLE ASSETS AND INTELLECT

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	9 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	NOTE 6 – INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months. The Company will receive all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S. The Technology Platforms include but are not limited to: A. Proteomic research platforms which include proprietary blends. B. Combination design Techniques C. Patent Pending Proprietary Blends D. Patent Pending Formulas E. Trademarks and all pending Trademarks F. 510K USA FDA, information and Know-how for application G. All Clinical trials, (Right to use) H. CE mark (International) I. Regenerex Library formula incorporated in the Wound Healing Technology. J. Wound Healing Technology QBX K. Synthetic Compositions of Cations derived from botanical material in the ash of Red- Oak Bark. Products: 1. Xcellderma over the counter product. 2. Accelerex, combination product as a drug device. 3. Accelerex in a tube.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7 – COMMITMENTS AND CONTINGENCIES The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers. See Note 6 for discussion of the $10,000,000 in contingent consideration to be paid in connection with the November 15, 2021 Asset Purchase Agreement. To date, no amounts have been payable under this agreement.

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	9 Months Ended
	Dec. 31, 2021
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 8 – STOCKHOLDERS’ DEFICIT During the three months ended December 31, 2021, Irene Getty, who resigned as a member of the Board of Directors, transferred 45,000,000 shares of common stock with an estimated fair value of $45,000 to Gregory Pilant and Deborah Pilant upon their appointment as Directors and Officers of the Company. Irene Getty continues to be the Chief Financial Officer of the Company. Irene Getty was a significant shareholder owning more than 10% of the shares outstanding at the time. The Company recognized stock-based compensation of $45,000 within general and administrative expenses in the accompanying statement of operations related to this transfer of shares. See Note 6 for shares issued in connection with the Asset Purchase Agreement.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 – SUBSEQUENT EVENTS On January 20, 2022, a note to a shareholder that was originally due on January 20, 2022 with a principal amount of approximately $8,000 ($10,000 Canadian Funds) was reissued in the principal amount of approximately $10,000 ($12,000 Canadian Funds), which included the original principal amount plus interest accrued as at January 20, 2022 in the approximate amount of $2,000 ($2,000 Canadian Funds). Repayment of the note is due no later than January 20, 2024. On January 31, 2022, a note to a shareholder that was originally due on January 31, 2022 with a principal amount of approximately $53,000 ($70,000 Canadian Funds) was reissued in the principal amount of approximately $66,000 ($84,000 Canadian Funds), which included the original principal amount plus interest accrued as at January 31, 2022 in the approximate amount of $11,000 ($14,000 Canadian Funds). Repayment of the note is due no later than January 31, 2024.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government. The Company defers revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1.
Earnings per Share	Earnings per Share Earnings per share is reported in accordance with FASB Accounting Standards Codification (“ASC”) Topic 260 “ Earnings per Share December 31 , 2021 and 2020, the Company does not have any common share equivalents outstanding.
Website	Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2021 and 2020 was $ and $ and $ and $ , respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

NATURE OF OPERATIONS (Details N

NATURE OF OPERATIONS (Details Narrative) - USD ($)	9 Months Ended
	Dec. 31, 2021	Nov. 15, 2021
Entity Incorporation, Date of Incorporation	Nov. 18, 2005
Asset Acquisition, Contingent Consideration, Liability		$ 10,000,000
Purchase Intellectual Property [Member]
Shares, Issued		150,000,000

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stockholders' Equity Attributable to Parent	$ 937,168	$ 902,734	$ 835,026	$ 550,546	$ 516,863	$ 481,274

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Amortization of Intangible Assets	$ 1,016	$ 2,329	$ 504	$ 4,167

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021
Related Party Transaction [Line Items]
Related Party Advances	$ 131,447	$ 131,447	$ 131,447		$ 130,992
Interest Expense, Related Party			9,879	$ 9,869
Debt Instrument, Maturity Date Range, Start		Jan. 20, 2022
Debt Instrument, Maturity Date Range, End		Dec. 30, 2023
Notes Payable	$ 349,754	$ 349,754	349,754		224,177
Debt Instrument, Maturity Date, Description	due twenty-four (24) months after the date of issue
Accrued Interest	$ 42,676	42,676	42,676		33,132
April 15 Note 2021 [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	$ 86,000	86,000	86,000
Debt Instrument, Maturity Date	Apr. 15, 2023
October 11 Note 2021 [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	$ 12,000	12,000	12,000
Debt Instrument, Maturity Date	Oct. 11, 2023
October 21 Note 2021 [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	$ 36,000	36,000	36,000
Debt Instrument, Maturity Date	Oct. 21, 2023
October 25 Note 2021 [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	$ 29,400	29,400	29,400
Debt Instrument, Maturity Date	Oct. 25, 2023
December 9 Note 2021 [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	$ 5,000	5,000	5,000
Debt Instrument, Maturity Date	Dec. 9, 2023
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Related Party Advances	$ 455	455	455	$ 0
Note Payable To Shareholder [Member]
Related Party Transaction [Line Items]
Long-term Debt, Fair Value	$ 468,607	$ 468,607	$ 468,607		$ 374,271
Debt Instrument, Interest Rate, Stated Percentage	10.00%	10.00%	10.00%		10.00%
Notes Payable	$ 67,082	$ 67,082	$ 67,082

INTANGIBLE ASSETS AND INTELLE_2

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)	1 Months Ended
	Nov. 15, 2021shares
Goodwill and Intangible Assets Disclosure [Abstract]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	150,000,000
Business Combination, Contingent Consideration Arrangements, Description	up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Share-based Payment Arrangement, Noncash Expense	$ 45,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended
	Jan. 31, 2022	Jan. 20, 2022
Promissory Note 1 [Member]
Short-term Debt [Line Items]
Debt Instrument, Issuance Date		Jan. 20, 2022
Debt Instrument, Face Amount		$ 10,000
Debt Instrument, Maturity Date		Jan. 20, 2024
Promissory Note 2 [Member]
Short-term Debt [Line Items]
Debt Instrument, Issuance Date	Jan. 31, 2022
Debt Instrument, Face Amount	$ 66,000
Debt Instrument, Maturity Date	Jan. 31, 2024